<DOC>
	<DOCNO>NCT02460367</DOCNO>
	<brief_summary>This Phase 1/2 trial use indoximod , inhibitor immune `` checkpoint '' pathway indoleamine 2,3-dioxygenase ( IDO ) , combination Tergenpumatucel-L immunotherapy Docetaxel treat subject advance Non-Small Cell Lung Cancer ( NSCLC ) . From practical standpoint , successful tumor immunotherapy likely require combination treatment additional therapeutic intervention activate immune response remove redundant mechanism tolerance maintenance . This clinical trial utilizes combination chemotherapeutic agent , docetaxel , plus two investigational method cancer immunotherapy : first , tergenpumatucel-L , intended educate human immune system recognize abnormal component find lung cancer cell , result immune response intend destroy block growth cancer ; second , IDO inhibitor Indoximod , overcome tumor-induced immune suppression . The goal study assess progression-free survival ( PFS ) overall survival ( OS ) rate patient population . This study provide foundation future trial test indoximod combine tergenpumatucel-L .</brief_summary>
	<brief_title>Immunotherapy Combination Study Advanced Previously Treated Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>Inclusion Criteria Histological/cytological diagnosis nonsmall cell lung cancer ( NSCLC ) . Squamous cell ( epidermoid ) , adenocarcinoma , bronchoalveolar carcinoma large cell anaplastic lung carcinoma histology eligible . Mixed histology NSCLC ( i.e. , adenosquamous ) eligible . Mixed NSCLC/small cell lung carcinoma ( SCLC ) , variant large small cell lung cancer NOT eligible study . Measurable disease define RECIST 1.1 Criteria . At least one three prior line therapy advance stage allow . One prior line therapy must platinum doublet chemotherapy . At least 18 year age . ECOG performance status ≤ 1 Normal bone marrow organ function define : Marrow : Hemoglobin ≥10.0 gm/dL , absolute granulocyte count ( AGC ) ≥1,000/mm3 platelet ≥100,000/mm3 , absolute lymphocyte count ≥1000/mm3 . Hepatic : Serum/plasma total bilirubin ≤1.5 x upper limit normal ( ULN ) exception &lt; 2.9 mg/dL patient Gilbert 's disease , ALT ( SGPT ) AST ( SGOT ) ≤2.5 x ULN . Renal : Serum/plasma creatinine ( sCr ) ≤1.5 x upper limit normal , creatinine clearance ( Ccr ) ≥50 mL/min . Serum/plasma albumin &gt; 3.0 gm/dL Sexually active woman childbearing potential must agree use two form contraception prior study entry duration study participation . A pregnancy test require prior study enrollment monthly treatment indoximod woman child bear potential . Also men discourage father child treatment . Ability understand willingness sign IRB approve write informed consent document . Exclusion Criteria More three line prior therapy . Previous use indoximod tergenpumatucelL immunotherapy . A history malignancy , unless treat curative intent , evidence disease least 2 year . Current therapy investigational agent . Untreated CNS disease , metastases carcinomatous meningitis . Patients CNS metastasis must least 2 week status post prior therapy brain steroid without progress CNS disease symptom . History allergic reaction attribute compound similar chemical biologic composition indoximod , docetaxel , agent use study . Current use immunosuppressive drug use corticosteroid , except inhaler , topical corticosteroid , dexamethasone premedication docetaxel . Other malignancy within three year , unless probability recurrence prior malignancy &lt; 5 % . Patient 's curatively treat squamous cell carcinoma basal cell carcinoma skin carcinoma situ uterine cervix ( CIN ) patient history malignant tumor past disease free least five year also eligible study . History organ transplant . Any follow within 6 month prior study drug administration : Myocardial infarction Severe/unstable angina Coronary/peripheral artery bypass graft Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Pulmonary embolism Uncontrolled intercurrent illness include , limited , ongoing active infection , uncontrolled ongoing cardiac dysrhythmias ≥ grade 2 , psychiatric illness/social situation would limit compliance study requirement Pregnant and/or breastfeed . Women childbearing potential must negative pregnancy test within 14 day study entry . Known HIVpositivity combination antiretroviral therapy unknown potential pharmacokinetic interaction indoximod , docetaxel . In addition , patient increase risk lethal infection treat marrow suppressive therapy . Active autoimmune disease require systemic therapy . Patients history autoimmune disease must counsel regard unknown potential exacerbate reactivate previous dormant autoimmunity consent process .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>Vaccine Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Second line therapy</keyword>
	<keyword>Progressive</keyword>
	<keyword>Relapsed</keyword>
	<keyword>IDO</keyword>
	<keyword>IDO Inhibitor</keyword>
</DOC>